Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential XELOX and TX in Gastric Adenocarcinoma
NCT01558011Phase 2Terminated
- Sponsor
- National Health Research Institutes
- Start
- Mar 2012
- Primary completion
- Oct 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin, docetaxel in gastric adenocarcinoma, sponsored by National Health Research Institutes. Started Mar 2012; status: terminated.
02
Drugs
capecitabineoxaliplatindocetaxel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT01558011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558011.